Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Inventory (2022 - 2026)

Gyre Therapeutics has reported Inventory over the past 4 years, most recently at $10.2 million for Q4 2025.

  • Quarterly Inventory rose 60.5% to $10.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.2 million through Dec 2025, up 60.5% year-over-year, with the annual reading at $10.2 million for FY2025, 60.5% up from the prior year.
  • Inventory was $10.2 million for Q4 2025 at Gyre Therapeutics, up from $8.9 million in the prior quarter.
  • Over five years, Inventory peaked at $10.2 million in Q4 2025 and troughed at $4.3 million in Q4 2023.
  • The 4-year median for Inventory is $6.4 million (2024), against an average of $6.9 million.
  • Year-over-year, Inventory plummeted 30.07% in 2023 and then soared 60.5% in 2025.
  • A 4-year view of Inventory shows it stood at $6.1 million in 2022, then plummeted by 30.07% to $4.3 million in 2023, then soared by 48.03% to $6.3 million in 2024, then surged by 60.5% to $10.2 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Inventory are $10.2 million (Q4 2025), $8.9 million (Q3 2025), and $8.9 million (Q2 2025).